推动亚洲寡核苷酸与多肽疗法从临床研发迈向生产制造

Dr. Alap Gandhi, Country Medical Director, GSK Malaysia, brings with himself over 17 years of experience in the healthcare industry having worked with organizations like WHO, GSK and AstraZeneca pharmaceuticals.

Dr. Alap Strongly believes in the purpose to unite science, technology, and talent to get ahead of disease together and positively impact the health of billion people. 

His interests include application of the science of medicines and vaccines from early development and throughout the lifecycle to deliver improvement in patient and population health outcomes. Dr. Alap is MBBS, MD and has additional qualifications of eMBA, PDCR and PGCDDR (Kings College, London).

Wonil Kim, Ph.D., is Chief Scientific Officer at Aston Sci, Inc., where he leads the development of mRNA-based vaccines for oncology and infectious diseases using the AI-driven Th-Vac® platform. He earned his Ph.D. in Molecular, Cellular, Developmental Biology and Genetics from the University of Minnesota and completed postdoctoral fellowships at Harvard Medical School and the NIH. Dr. Kim has served as a Staff Scientist at St. Jude Children's Research Hospital, where he pioneered cancer biology programs, and has held senior R&D positions at GeneOne Life Science and Cyrus Therapeutics. He is recognized for his expertise in mRNA vaccine design and cancer immunology.

Dr. Xian Zeng, the Co-Founder and CEO of Byterna Therapeutics, leads this enterprising startup at the vanguard of groundbreaking circular mRNA-based immunotherapies.

Holding a PhD in pharmaceutical science from the National University of Singapore, he previously served as Associate Professor at Fudan University School of Pharmacy, spearheading interdisciplinary research in AI-empowered mRNA drug discovery.

Under his visionary leadership, Byterna is pioneering SEAA (Safe, Effective, Accessible, Affordable) in vivo CAR-T therapies for global patients, leveraging proprietary circular mRNA platforms and targeted delivery systems.